Patient Groups

Integrity and transparency determine our interactions with Patient Groups

Roche is convinced that an open dialogue and transparent exchange of information with patient groups is vital.

Building and sustaining relationships with patient groups is an efficient way to get valuable insights that influence Roche’s work across therapeutic areas – from drug development to regulatory approval and reimbursement into product launch and marketing. We are increasingly partnering with patient groups on projects ranging from disease awareness campaigns to clinical trial design.

Roche works with a wide range of patient groups in a variety of different areas, e.g. oncology, viral diseases, metabolic diseases and central nervous system diseases.

Patient groups provide patients with support and information on how to live with their disease, represent patient views and campaign for change on issues that affect patients’ lives.

Different stakeholders, e.g. governments, trade associations (such as EFPIA and AdvaMed), the public and the media, call for integrity and transparency in terms of how industry interacts with patient groups and request the disclosure of financial and in-kind support provided by industry. Annually, Roche publishes the names of all patient groups it works with globally, and the support provided to them, on various channels.

Roche consistently applies high standards of conduct in its interactions with patient groups. All relationships with patient groups are based on the common values of integrity, independence, respect, equity, transparency and mutual benefit. These standards are set forth in the “Roche Good Practice Guidelines on Working with Patient Groups”.

We are all expected to:
  • Respect patient groups as an important stakeholder.
  • Base relationships and interactions with patient groups on the standards of integrity, independence, respect, equity, transparency and mutual benefit.
  • Sustain our relationships with patient groups.
Questions & Answers

Are open dialogue and the transparent exchange of information with patient groups adding value to Roche’s business?

Yes. Patient groups offer Roche valuable insights that influence our work across therapeutic areas – from drug development to regulatory approval and reimbursement into product launch and marketing.

I am working in the Sales Department. In order to increase the sales I intend to give a substantial financial contribution to a patient group as a return for the patient group’s public support of the Roche product I am responsible for. Is this behaviour correct?

No. You must respect the independence of the patient group and are not allowed to abuse the patient group as a marketing tool. Keep in mind that advertising of a prescription-only medicine to the public is prohibited in most countries (except in the USA and New Zealand, which currently allow direct-to-consumer advertising).

Further Informations

Further information and guidance: Industry codes (e.g. EFPIA Patient Organisation Code of Practice); Roche Position Paper on Working with Patient Groups; Roche Good Practice Guidelines on Working with Patient Groups. These documents can be found on the Roche intranet (website of Group Legal Department) and partially on the Roche internet.
Help & advice: In case of questions regarding interactions with patient groups, please contact your Line Manager, the local Compliance Officer, the Chief Compliance Officer or the Roche Group Code of Conduct Help & Advice Line.
Speak up: If you believe in good faith that in connection with a business where Roche is involved someone has done, is doing, or may be about to do something that violates the provisions regarding interactions with patient groups, speak up by using the available speak up channels.